Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome
Open Access
- 24 July 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba5379
Abstract
Auroliposome represents a highly effective siRNA delivery platform for in vitro and in vivo application.Keywords
Funding Information
- NIH Office of the Director (CA 213278)
- NIH Office of the Director (2CA136494)
- NIH Office of the Director (P30CA225500)
This publication has 40 references indexed in Scilit:
- Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug ResistancePLOS ONE, 2013
- Cystathionine β-synthase-derived hydrogen sulfide regulates lipopolysaccharide-induced apoptosis of the BRL rat hepatic cell line in vitroExperimental and Therapeutic Medicine, 2012
- Tuning the size of gold nanoparticles in the citrate reduction by chloride ionsNanoscale, 2012
- Uptake mechanisms of non-viral gene deliveryJournal of Controlled Release, 2012
- Endocytosis via caveolae: alternative pathway with distinct cellular compartments to avoid lysosomal degradation?Journal of Cellular and Molecular Medicine, 2009
- Lipid–Gold‐Nanoparticle Hybrid‐Based Gene DeliverySmall, 2008
- Loading of gold nanoparticles inside the DPPC bilayers of liposome and their effects on membrane fluiditiesColloids and Surfaces B: Biointerfaces, 2006
- Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA DeliveryCancer Research, 2005
- Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 2005
- RNA interference in adult miceNature, 2002